Clinical
New COPD inhalers
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.Bookmark
Record learning outcomes
Sandoz recently launched AirFluSal Forspiro (fluticasone propionate plus salmeterol), a new twice-daily dry powder inhaler (DPI) for the treatment of COPD.
The company says that Forspiro offers several features that make the device easy to use and aid compliance, including a dose counter; a window showing empty blisters; a tear-off foil strip enabling patients to ensure they have taken two doses per day; and a simple lever arm to load the dose.
Meanwhile, Chiesi’s DPI Fostair NEXThaler (beclomethasone and formoterol) has been granted a licence extension for patients with severe COPD and a history of repeated exacerbations, who have significant symptoms despite regular long-acting bronchodilators.
Again, the manufacturer says the device has several features that improve adherence. For example, Chiesi points out that, “whereas dose counters on other dry powder ICS/LABA combination products record the number of times the device has been primed or loaded, the dose counter on the NEXThaler device decreases only after successful inhalationâ€.